<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 151 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page150.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=151">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 151 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 151</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=151"><img src="../thumb/151.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>120 / 2020-04                                                        Cardio-Vascular Agents - 7.3.9

              THE NOAC* YOU AND YOUR PATIENTS CAN RELY ON


                *NOAC = non-vitamin K oral anticoagulant

   (S3) TABS, 42/7.1.3/0437, 0438  substit. contain. K/meds poss.incr.ser.K may lead to incr. ser.K., less   Contraindications: Pregn., safety in lactat.not est., mod.to sev.
   721259-001: 50 mg, 30, R95,40  eff.low.BP in black people, ischaem. cardiopathy/ ischaem.card.vasc.  ren.impairm.
   721260-001: 100 mg, 30, R90,60  dis., monit.BP & adjust. meds. that lower BP if appropr.when init. ther.  Side effects: Freq: Headache, dizzin., vir.infect., URTI, cough, GI
   Dosage: Init.& maint dos: 50 mg once dly. Max. eff. attain.3-6   for CV morbid.& mortal.prevent.  disturbs., fatig., rhinit., sinusit., back/ abdom.pain, pharyngit., ar-
   wks.aft.init.ther. May be incr.to 100 mg once dly. May be admin.  Interactions: Li conc.& toxic., incr.eff.of other anti-hypertens., incr.  thralg. Less freq: Oed., asthen., insomn., rash, decr.libido, vertigo.
   with other antihypertens.    digox.plasma conc., incr.in ramipril & ramiprilat AUC & C max,  ac.ren.  Unknown freq: Hypersens.reacts.incl. angioed./ ser. sickn. & vas-
   Vol.-deplet.pts/pts.with imp.hepat.funct: Start.dos: 25 mg   insuff. potent. with concom.NSAID’s in dehydrat.pts., reduc. antihy-  culit., neutropen., elev. liv. funct. values.
   once dly.                    pertens.eff.with NSAID’s, incr. adverse eff.with concom.ACE inhib-  Warnings and special precautions: Teratogenic. in experim.
   Contraindications: Angioed.hist.link.to prev.ACE inhibit./angio-  its./ARB’s & aliskiren, ac.kidn.injury with concom. fluoroquinolones,  anim., discont if pregn. detect., correct. Na & vol.deplet.bef.init.ther.,
   tens.recept.block ther., heredit./ idiopath. angioed., hypertroph.  safety & effic.in childr.not est., monit.bld.urea & ser. creatinine in pts.
   obstruct. cardiomyopathy, mod.to sev.ren.funct.impairm. (creatin.   RASOL, Novagen [P/S}  with bilat.& unilat.ren.artery stenos., bil.-obstruct.disords., concom.K -
                                                                          -
                                                                    -
   clear.&lt;30ml/min)., bil.ren.artery/aort. stenos., ren.artery stenos.  Losartan  -spar. diuret., K supplem.or Ksalt substit.,
                     +
   with sngl.funct.kidn., aort. stenos., concom.K  spar.diuret./Li ther.,   Indications: Hypertens.  Interactions: Incr.ser.K+ lev with K-spar. diuret./ K supplem.or
                                                                              -
                                                                                     -
   porphyr., safety in pregn.& lactat.not est., safety & effic. in childr.  (S3) TABS, 43/7.1.3/0497, 0498  Ksalt substit.
                                                               -
   not est., lact.intol.        717295-001: 50 mg, 30, R88,85
   Side effects: Orthostat.hypotens., dizzin., headache, skin reacts.,   717296-001: 100 mg, 30, R88,85  TELGEN, Ranbaxy [P/S]
   asthen., fatig., back/chest pain, oed., palpitat., tachycard., GI   Dosage: Init.& maint dos: 50 mg once dly. Max.eff.attain.3-6 wks.  Telmisartan
   disturbs., musc. cramps,/ pain, insomn., migraine, URTI, cough,   aft.init.ther. May be incr.to 100 mg once dly. May be admin.with   Indications: Mild to mod.hypertens.alone/ combin. with hydro-
   nas. congest., sinus disord., pharyngit., angioed., poss. ren. fail.in   other antihypertens.  chlorothiazide.
   imp.ren.funct., hyperkalaem., ALT elev.  Contraindications: Angioed.hist.link.to prev.ACE inhibit./angiotens.  (S3) TABS, 45/7.1.3/0610, 0611
   Warnings and special precautions: No re-challenge aft.   recept.block ther., heredit./ idiopath. angioed., hypertroph.obstruct.   720592-001: 40 mg, 30, R129,82
   angioed.react., poss.tox.Li bld.conc. with concom.use, discont.  cardiomyopathy, mod.to sev.ren.funct.impairm. (creatin.clear.&lt;30ml/  720593-001: 80 mg, 30, R129,82
   ther.with pregn. plann./ confirm., adeq.contracept.for women of   min)., bil.ren.artery/aort. stenos., ren.artery stenos.with sngl.funct.  Dosage: Recomm.dos: 20 mg or 40 mg once dly. Max: 80 mg once
                                       +
   childbear. age, Na/vol.deplet.to be correct.bef.init.ther./ admin.   kidn., concom. K  spar.diuret./Li ther., porphyr., Addison’s dis. combin.  dly. May be used in combin.with low dos. thiaz.diuret. Max.antihy-
   low.dos., hepat.impairm.hist., imp.ren. funct./ where ren.funct.  with thiaz.diuret., anur., sulphonam.-deriv. sens., safety in pregn.& lac-  pertens.eff.is gen. attain.4-8 wks.aft.start of treatm.
   depend.on renin-angiotensin-aldoster.syst.eg.sev.CHF, bil.ren.art.   tat. not est., safety & effic.in childr.not est., lact.intol.  Mild to mod.hepat.impair: Do not exceed 40 mg once dly.
   stenos./ stenos.of art.to solit.kidn., monit.ser.K+ conc. in elderly/  Side effects: Orthostat.hypotens., dizzin., headache, skin reacts.,   Contraindications: Angioed.hist.link.to prev.ACE inhibit./angiotens.
   ren.funct.impairm.           asthen., fatig., back/chest pain, oed., palpitat., tachycard., GI dis-  recept.blocks., heredit./idiopath. angioed., hypertroph.obstruct.cardio-
   Interactions: Eff.potent.by meds./other agents low. BP, poss.  turbs., musc. cramps, insomn., migraine, URTI, cough, nas. con-  myopathy, sev. ren. impairm., bil.ren.artery stenos., ren.artery stenos.
                                                                              +
                   +
   hyperkalaem.eff.with K -spar. diuret./ K supplem./other agents   gest., sinus disord., pharyngit., angioed., poss. ren.fail.in imp.ren.  to sngl.kidn., aort.stenos., concom.Li/K spar. diurets., porphyr., safety
             +
   caus. hyperkalaem., NSAID’s may antagon.eff., poss. interacts.   funct., hyperkalaem.  in pregn.& lactat.not est.
   with drugs aff.cytochrome P450 syst.  Special precautions: No re-challenge aft. angioed. react., poss.  Side effects: UTI, URTI, bld.dyscras., angioed., psych./ GI disords.,
                                tox.Li-conc., discont.ther.with pregn. plann./confirm., adeq.contra-  CNS effs., abnorm.vis., vertigo, tachycard., bradycard., hypotens.,
   PRITOR, Ing.Pharm. [P/S] &   cept.for women of childbear.age, vol.deplet.to be correct. bef.init.   cough, dyspn., skin reacts., incr.sweat., arthralg., myalg., back pain,
   Telmisartan                  ther./ admin.low.dos., hepat.impairm.hist., where ren. funct.depend.  leg cramp/pain, tendonit./flu-like sympt., weakn., chest pain, lack of
   Indications: Mild to mod.hypertens.alone/ combin. with hydrochlo-  on renin-angiotensin-aldoster. syst., eg.sev.CHF, ren artery stenos.  effic., dizzin., drowsin., hyperkalaem.
   rothiazide, cardiovasc. morbidit.& mortalit.reduct.in pts.55 yrs or old.  Drug interactions: Eff.potent.by meds./other agents low.BP, poss.  Warnings and special precautions: No re-challenge aft.angioed.
   at high risk of CV dis.      hyperkalaem.eff.with K -spar. diuret./ K supplem./other agents caus.   react., Li/digox.ther., treatm. to be stopp.& chang.if pregn.occurs/
                                                +
                                          +
   (S3) TABS, 33/7.1.3/0022, 0023  hyperkalaem., NSAID’s may antagon.eff., poss. interacts. with drugs   plan., ensure effect.contracept.in women of childbear.age, mild to
   714249-001: 40 mg, 28, R197,98  aff.cytochrome P450 syst.  mod.hepat.impairm., safety & effic.in childr. und. 18 yrs.not est., incr.
   714250-001: 80 mg, 28, R197,98                             sev.hypotens.& ren.insuff. risk with bil.ren.artery stenos./ren.artery
   Dosage: Adults: Essential hypertens: Recomm. dos: 40 mg once   SPEC LOSARTAN, Specpharm [P/S]  stenos.to sngl. funct.kidn., vol./Na deplet.to be correct.bef. init. ther.,
   dly. Incr.to max.of 80 mg once dly. as indicat.by respons.or use altern.  Losartan  not recomm.in prim.aldosteronism, when vasc.tone & ren.funct.de-
   in combinat. with low dos hydrochlorothiaz.(12,5 mg). Max. anti-hy-  Indications: Hypertens.  pend.predomin.on renin angiotens.-aldosterone syst.activ., concom.
                                                                            +
   pertens. eff.gen.attain.4-8 wks.aft.start of treatm.   (S3) TABS. 41/7.1.3/1076, 1075  meds. affect.that syst., per.monit.K /creatin.lev.of risk pts., no exper.
                                                                          +
   Cardiovasc.morbidit. & mortalit. reduct: Recomm. dos: 80 mg   713255-001: 50 mg, 30, R90,08  in ren.transplant., concom. K spar. diuret./K supplem.or salt substit.
                                                                                +
                                                                  +
                                                                                   +
   once dly. Treatm.benef. evid.aft.6 mnths.of contin.ther.   713254-001: 100 mg, 30, R101,75  contain. K / meds.poss.incr.ser.K  lead.to incr.ser.K not to be admin.
                                                                            +
   Mild to mod.hepat.impairm: Do not exceed 40 mg once dly.  Dosage: Init & maint dos: 50 mg once dly. Max. eff. attain. 3-6   concom., bil.obstruct.disords./hepat. insuff., baseline GI dis.as GI
   Contraindications: Angioed.hist.link.to prev. ACE inhibit./angioten-  wks.aft.initiat. May be incr.to 100 mg once dly. May be admin.with   bleed.report., less eff. in low.BP in black people, excess.BP reduct.in
   sin recept.block., heredit./ idiopath. angioed., hypertroph.obstruct. car-  other antihypertens.  ischaem. cardiopathy/ischaem.card.vasc.dis.may result in MI/stroke,
   diomyopathy, bil.ren.artery stenos., ren.artery stenos. sngl.funct.kidn.,   Contraindications: Angioed.hist.link.to prev. ACE inhibit./angio-  unsuit.for fruct.intol.pts.
   aort.stenos., concom. Li/K spar. diuret., porphyr., sev.ren.impairm.,   tensin recept.block., heredit./ idiopath. angioed., aort.stenos., hyper-  Drug interactions: Incr.eff.of other antihypertens., incr.digox.plasma
              +
   pregn., lactat., sev. hepat. impairm., bil.obstruct.disords., fruct.intol.,   troph. obstruct. cadiomyopathy, mod.to sev.ren.funct. impairm. (cre-  conc., incr.ser.Li conc. & toxic.
   concom.aliskiren-contain.meds., concom.fluoroquinolones in mod.-  atinine clear.&lt;30 ml/min.)., bil.ren. artery stenos., ren.artery stenos.
   sev.ren. impairm.& elderly, safety & effic.in childr.und.18 yrs.not est.  sngl.funct.kidn., concom.Li/K spar.diuret., pregn., lactat., safety &   TELPRES PLUS, Sandoz.
                                            +
   Side effects: Common: Cough. Uncommon: UTI, URTI, anaem.,   effic.in childr.not est.  Telmisartan 40(80) mg, hydrochlorothiaz.12,5(12,5) mg
   hyperkalaem., depress., insomn., syncope, faint., vertigo, bradycard.,   Side effects: Symptomat.hypotens., URTI, symptomat. anaem.,   Indications: Mild to mod.hypertens.in pts. stabilis. on same dos.
   hypotens., orthostat.hypotens., dyspn., abdom.pain, diarrh., dyspeps.,   decr.Hb, neutropen., thrombocytopen., angioed., insomn., head-  of indiv.compon.
   flatul., vomit., incr.sweat., prurit., rash, back pain, musc.spasms, leg   ache, dizzin., migraine, palpitat., tachycard., hypotens., vasculit.,   (S3) TABS, 46/7.1.3/0930.927, 0931.928.
   cramps, myalg., ren.impairm.incl.ac.ren.fail, chest pain,asthen./   cough, nas.congest., pharyngit., sinus disords., GI disturbs., taste   3000422-001: 40/12,5 mg, 28, R112,77
   weakn., incr.bld.creatinine. Rare: Thrombocytopen., hypersens.   disturbs./loss thereof, hepatit., sev.ac.hepatotoxic., cholestas., ur-  3000423-001: 80/12,5 mg, 28, R112,77
   incl.angioed.with fatal outcome, anx., vis. disturbs., tachycard., dry   ticar., rash, prurit., atypic.cutan.lymphoid infiltrat., psorias., back &   Dosage: Admin.once dly.with/without food. Two dos.strengths are
                                                                 st
   mouth, stomach discomf., eczema, erythema, drug erupt., tox.skin   leg pain, musc.cramps, myalg., arthralg., rhabdomyolys., imp.ren.  provid.1  stabilis.pt.on relev. dos. of indiv.compon.giv.tog.then change
   erupt., arthralg., leg pain, flu-like sympts., Hb decr., bld.uric acid/-  funct., ac. pancreatit., asthen., fatig., chest pain, oed., incr. liv. en-  to appropr. combinat. Cont.for at least 4-8 wks.to obt. max.eff. May
   creatine phosphokin. incr. hepat.enzym.incr. Post market: Sepsis incl.  zyme val., hyperkalaem.  be admin.with other antihypertens. meds.Do not exceed 40/12,5 mg
   fatal outcome, eosinophil., anaphylact. react., urticar., tendonit.like   Special precautions: Adeq.contracept.for women of childbear.age,   once dly in pts with mild to mod.hepat.impairm.
   sympts., hypoglycaem. in diab.pts., abnorm.hepat.funct., liv.disords.,  ren.artery stenos., aort. valve stenos., hypertroph.obstruct. cardiomy-  Contraindications: Angioed.hist.link.to prev.ACE inhibit./angio-
   Warnings and special precautions: No re-challenge aft.angioed.  opathy, hepat.impairm., teratogen.in experim. animals, vol.deplet.,   tensin recept.block.in which case pts. never to receiv.these meds
   react., treatm.to be stop.& chang. if pregn.occurs/plan., monit.plasma   monit.ser. K  conc., where ren.funct.depend.on renin-angiotensin-  again, heredit./ idiopath. angioed., hypertroph.obstruct. cadiomyo-
                                     +
   digox.& Li lev.with concom.ther., adeq.hydrat.& monit. ren. funct.at   aldoster. syst.eg.sev.CHF.  pathy, sev.ren.funct.impairm.(creatinine clear.&lt;30 mL/min.)., bil.
   begin.of combin.treatm.with concom. NSAID’s, adeq.contracept.in   Drug interactions: NSAID’s may antagon.eff., sympathomim.  ren.artery stenos., ren. artery stenos.with sngl. kidn., aort.stenos.,
                                                                                        +
                                                                   +
                                                                         +
   fertile women, human embryon./ fetotox./neonat.toxic.report., mild   may reduc.eff., poss.hyperkalaem. with K -spar.diuret./K -contain.  concom. Li/K spar.diuret./K supplem/salt substit./ meds incr. K lev.,
                                                        +
                                                  +
   to mod. hepat.impairm., biliary obstruct.disords., when vasc.tone &   meds.or K  supplem.  porphyr., pregn.& lactat., concom. renin inhibit.eg aliskiren-contain.
                                     +
   ren.funct.depend.predomin.on renin angiotensin-aldosterone syst.ac-  meds., bil.obstruct.disords., sev.hepat.impairm., bil. cirrhos., choles-
   tiv., dual block. of RAAS with ARB’s/ACE inhibit./aliskiren assoc. with   TAREG, Novartis [P/S]  tas., refract.hypokalaem./ hyponatraem./hypercalcaem.& sympto-
   high.freq.hypotens./hyperkalaem.& decr. ren.funct.(incl.ren.fail), incr.  Valsartan.  mat. hyperuricaem.,
   sev.hypotens.& ren. insuffic.risk with bil.ren.artery stenos./ren. artery   Indications: Mild to mod.hypertens.  Side effects: Bronchit., pharyngit., sinusit., angio-oed., exacerb./ac-
   stenos.sngl.funct.kidn., monit.ser.K & creatinine of risk pts., no exper.  (S3) TABS. 36/7.1.3/0067, 0068  tivat.SLE, hypokalaem., hypoglycaem., hyponatraem., hypochloraem.,
   in ren.transplant., vol./ Na deplet.to be correct.bef.init.ther., assess   705060-001: 80 mg, 28, R153,01  anx., depress., dizzin., syncope, paraesthes., sleep disturbs.,insomn.,
   ren. funct.bef.init.treatm.& monit.dur.treatm.with fluoroquinolones/   704696-001: 160 mg, 28, R153,01  vis.disturbs., vertigo, tachycard., card.dysrhythm., hypotens., orthos-
   ACE inhibit./angiotens.recept. block. whether used separat./concom.,   Dosage: Recomm.dos: 80 mg once dly. Substant. eff.pres.within 2   tat.hypotens., dyspn., resp. distress. incl.pneumonit.& pulm.oed., GI
   not recomm. in prim.aldosteronism, aort./mitral stenos., obstruct.hy-  wks.& max. eff.aft. 4 wks. May be incr.to 160 mg dly.or add diuret.  disturbs. incl.gastrit., abnorm.hepat.funct./ liv. disord., erythema,


   pertroph.cardiomyopathy, concom. Kspar. diuret./Ksupplem.or salt   in pts.not adeq. control. May be admin.with other anti-hypertens.  prurit., rash, incr.sweat., urticar., back/leg/chest pain, musc.spasm,
                        S4 Pradaxa ® . 110 mg. Each capsule contains 110 mg of dabigatran etexilate base (as mesilate salt). Reg. No. 42/8.2/0131. S4 Pradaxa ® . 150 mg. Each capsule contains 150 mg of dabigatran
                        etexilate base (as mesilate salt). Reg. No. 45/8.2/0162. For full prescribing information refer to the professional information approved by the Regulatory Authority.
                        Applicant details: Ingelheim Pharmaceuticals (Pty) Ltd, 407 Pine Ave, Randburg. Tel: +27 (011) 348-2400. Cpy. Reg. No. 1966/008618/07. BI Ref. No. PC-ZA-100406. Expiry date: August 2021.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page150.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page146.html">146</a>&nbsp;&nbsp;&nbsp;<a href="page147.html">147</a>&nbsp;&nbsp;&nbsp;<a href="page148.html">148</a>&nbsp;&nbsp;&nbsp;<a href="page149.html">149</a>&nbsp;&nbsp;&nbsp;<a href="page150.html">150</a>&nbsp;&nbsp;&nbsp;<a href="page151.html">151</a>&nbsp;&nbsp;&nbsp;<a href="page152.html">152</a>&nbsp;&nbsp;&nbsp;<a href="page153.html">153</a>&nbsp;&nbsp;&nbsp;<a href="page154.html">154</a>&nbsp;&nbsp;&nbsp;<a href="page155.html">155</a>&nbsp;&nbsp;&nbsp;<a href="page156.html">156</a>
             </td>
             <td width="35%"><a href="page152.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page152.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
